Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 4/20 | 0.41 |
| ▸ | PDE1A | P54750 | 4/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159304 | 0.82 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DCYP2A6 | |
| SCHEMBL30975093 | 0.82 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DCYP2A6 | |
| SCHEMBL30975091 | 0.82 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DCYP2A6 | |
| SCHEMBL17913144 | 0.81 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DCYP2A6 | |
| SCHEMBL2045719 | 0.81 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL3361877 | 0.81 | ACHE (0.62) | PDE4APDE4BPDE4CPDE4DCYP2A6 | |
| SCHEMBL703143 | 0.80 | PDCD1 (0.56) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL697285 | 0.80 | ACHE (0.56) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL806515 | 0.78 | CYP2A6 (0.52) | PDE4APDE4BPDE4CPDE4DCYP2A6 | |
| SCHEMBL17208935 | 0.77 | CYP2A6 (0.50) | PDE4APDE4BPDE4CPDE4DCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-2616460-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMA CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| EP-2364321-B1 | HCV inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | PDE4A 1951/4885PDE4B 1697/4885PDE4C 1789/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | PDE4A 749/4885PDE4B 917/4885PDE4C 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.